Evidence map›Paper›PMID 26170259›Full record

ArticleNeuro-oncology2015

PI3K pathway inhibition in GBM—is there a signal?

Donna Nichol, Ingo K Mellinghoff

Open access · bronzeAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Donna NicholHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York (D.N., I.K.M.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences, New York, New York (I.K.M.).
Ingo K MellinghoffHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York (D.N., I.K.M.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences, New York, New York (I.K.M.).
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Molecular Mechanisms of IDH1-mediated GliomagenesisR01NS080944 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2012 to 2016
$2.0M
NCI NIH HHS P30 CA008748NINDS NIH HHS 1R01NS080944-01NINDS NIH HHS R01 NS080944
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBrain NeoplasmsDacarbazineEverolimusFemaleGlioblastomaGonanesHumansMaleAntineoplastic AgentsDacarbazineEverolimusGonanes

Identifiers

PMID26170259
PMCPMC4588764
OpenAlexW2406263010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.